Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial

Journal:
The Lancet
Published:
Affiliations:
18
Authors:
20
Institutions Authors Share
Exelixis, United States of America (USA)
3.055556
0.15
City of Hope Comprehensive Cancer Center, United States of America (USA)
1.055556
0.05
UCLA Jonsson Comprehensive Cancer Center, United States of America (USA)
1.055556
0.05
Harbour Cancer and Wellness, New Zealand
1.055556
0.05
Bankstown-Lidcombe Hospital, Australia
1.055556
0.05
UPMC Hillman Cancer Center (UPCI), United States of America (USA)
1.055556
0.05
Samsung Medical Center (SMC), South Korea
1.055556
0.05
Groupe Hospitalier Diaconesses Croix Saint-Simon, France
1.055556
0.05
The Catholic University of Korea (CUK), South Korea
1.055556
0.05
University Hospital Saint-Luc, Belgium
1.055556
0.05
Korea University Anam Hospital, South Korea
1.055556
0.05
Vanderbilt University Medical Center (VUMC), United States of America (USA)
1.055556
0.05
Sarah Cannon Research Institute - UK, United Kingdom (UK)
1.055556
0.05
Siedlce University of Natural Sciences and Humanities, Poland
1.055556
0.05
University Cancer Center Hamburg (UCCH), UHH, Germany
1.055556
0.05
Hospital de la Santa Creu i Sant Pau, Spain
1.055556
0.05
Vall d'Hebron University Hospital (HUVH), ICS, Spain
0.555556
0.03
Catalan Institute of Oncology (ICO), Spain
0.555556
0.03